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Abstract: Hypertension is the number one diagnosis made by primary care physicians, placing 
them in a unique position to prescribe the antihypertensive agent best suited to the individual 
patient. In individuals with diabetes mellitus, blood pressure (BP) levels  130/80 mmHg 
confer an even higher risk for cardiovascular and renal disease, and these patients will benefit 
from aggressive antihypertensive treatment using a combination of agents. β‑blockers are play‑
ing an increasingly important role in the management of hypertension in high‑risk patients. 
β‑blockers are a heterogeneous class of agents, and this review presents the differences between 
β‑blockers and provides evidence‑based protocols to assist in understanding dose equivalence 
in the selection of an optimal regimen in patients with complex needs. The clinical benefits 
provided by β‑blockers are only effective if patients adhere to medication treatment long term. 
β‑blockers with proven efficacy, once‑daily dosing, and lower side effect profiles may become 
instrumental in the treatment of hypertensive diabetic and nondiabetic patients.
Keywords: antihypertensive, blood pressure, atenolol, carvedilol, labetalol, metoprolol, 
nebivolol
Introduction
Hypertension is one of the most common reasons for primary care physician visits and 
the number one diagnosis during appointments.1 Approximately 65 million Americans 
have hypertension, with a marked increase in prevalence among younger adults aged 
18–39 years, which may be related to the high obesity incidence in this country.2,3 The 
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC) guidelines are evidence‑based recommendations that integrate 
epidemiologic and clinical trial evidence about the health benefits associated with antihy‑
pertensive therapies into patient management decisions.4 The most recent JNC guidelines 
(JNC7) recommend maintaining a target blood pressure (BP) of  140/90 mmHg in 
patients with hypertension to reduce heart disease risk.5 To achieve BP control, the 
majority of patients with hypertension will need at least two medications from differ‑
ent pharmacologic classes. Patients with compelling indications such as heart failure 
(HF), myocardial infarction (MI), high coronary disease risk, and diabetes may need 
more aggressive treatment with three agents (Table 1).5
Of particular concern is the patient with concomitant diabetes or who is at high risk 
for diabetes. Patients with both hypertension and diabetes have a dramatically increased 
risk for cardiovascular complications, such as stroke and chronic kidney disease.6 Data 
from clinical studies emphasize the need for tight BP control in these patients. In the 
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UK Prospective Diabetes Study (UKPDS), 1,148 patients 
with type 2 diabetes and hypertension were randomized to 
more intense or less intense BP control and achieved BPs 
of 144/82 and 154/87 mmHg, respectively, using either 
an angiotensin‑converting enzyme inhibitor (ACEI) or a 
β‑blocker.7 Patients assigned to more intense BP control 
experienced risk reductions of 24% in diabetes‑related end‑
points, 32% in diabetes‑related deaths, 44% in stroke, 56% 
in HF, and 37% in microvascular endpoints. Treatment with 
either ACEIs or β‑blockers substantially reduced the risk of 
death and diabetes‑related complications.7,8
For patients with hypertension and diabetes, national 
organizations such as the National Kidney Foundation 
(NKF), American Diabetes Association (ADA), American 
Association of Clinical Endocrinologists (AACE), and 
the JNC recognize the serious risk and recommend 
BP control to 130/80 mmHg.5,9–11 Although national guide‑
lines emphasize the importance of maintaining BP control in 
people with hypertension, it has been reported that only 33% 
of physicians consider clinical practice guidelines as important 
for providing optimal disease management.12 Moreover, only 
25%–36% of all patients with hypertension reach target BP 
goals, although with intensive medication monitoring and 
titration up to 69% of patients may maintain BP control.13–16 
An analysis of data from The National Health and Nutrition 
Examination Survey (NHANES) 1988 to 2000 found that 
30% of patients with diabetes achieved their target BP 
(130/85 mmHg).16 The American College of Physicians 
recommends initiating antihypertensive therapy with a 
thiazide diuretic or an ACEI in patients with hypertension 
Table 1 Clinical trial and guideline basis for compelling indications for individual drug classes
High-risk condition  
with compelling  
indicationa
Thiazide-type 
diuretic
β-Blocker ACEI ARB CCB Ald Ant Guideline and/or 
clinical trial basisb
Heart failure X X X X X ACC/AHA heart failure 
guidelines, MERIT-HF, 
COPERNICUS, CIBIS, 
SOLVD,  AIRE, TRACE, 
Val-HeFT, RALES, 
CHARM
Post-myocardial  
infarction
X X X ACA/AHA post-
myocardial infarction 
guidelines, BHAT, SAVE, 
CAPRICORN, EPHESUS
High coronary  
disease risk
X X X X ALLHAT, HOPE, ANBP2, 
LIFE, CONVINCE, 
EUROPA, INVEST
Diabetes X X X X X NKF-ADA Guidelines, 
UKPDS, ALLHAT
Chronic kidney disease X X NKF Guidelines, 
 Captopril Trial, RENAAL, 
IDNT, REIN, AASK
Recurrent stroke  
prevention
X X PROGRESS
Notes: aCompelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed 
in parallel with the BP. bConditions for which clinical trials demonstrate benefit of specific classes of antihypertensive drugs used as part of an antihypertensive regimen to 
achieve BP goal to test outcomes.
Copyright © 2003.  Adapted with permission from Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
Abbreviations:  AASK, African-American Study of Kidney Disease and Hypertension; ACC/AHA, American College of Cardiology/American Heart Association; 
ACEI, angiotensin-converting enzyme inhibitor; AIRE, Acute Infarction Ramipril Efficacy; Ald Ant, aldosterone antagonist; ALLHAT, Antihypertensive and Lipid Lowering 
Treatment to Prevent Heart Attack Trial; ANBP2, Second Australian National Blood Pressure Study; ARB, angiotensin receptor blocker; BHAT, Beta-Blocker Heart Attack 
Trial; CAPRICORN, Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction; CCB, calcium channel blocker; CIBIS, Cardiac Insufficiency Bisoprolol Study; 
CONVINCE, Controlled Onset Verapamil Investigation of Cardiovascular Endpoints; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival; EPHESUS, 
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; EUROPA, European Trial on Reduction of Cardiac Events with Perindopril in Stable 
Coronary Artery Disease; HOPE, Heart Outcomes Prevention Evaluation; IDNT, Irbesartan in Diabetic Nephropathy Trial; INVEST, International Verapamil SR/Trandolapril 
Study; LIFE, Losartan Intervention for Endpoint Reduction; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; NKF-ADA, National 
Kidney Foundation-American Diabetes Association; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; RALES, Randomized Aldactone Evaluation Study; 
REIN, Ramipril Efficacy in Nephropathy; RENAAL, Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; SAVE, 
Survival and Ventricular Enlargement; SOLVD, Studies of Left Ventricular Dysfunction; TRACE, Trandolapril Cardiac Evaluation; UKPDS, UK Prospective Diabetes Study; 
Val-HeFT, Valsartan in Heart Failure Trial.
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and diabetes.17 In most cases, however, additional agents are 
required to achieve BP goals.5,18 Indeed, patients who are 
20/10 mmHg above their BP goal should initiate treatment 
with two antihypertensive agents that have complementary 
mechanisms in order to reach target BP and reduce cardio‑
vascular risk.5
The NKF, ADA, AACE, and JNC7 all include a 
 recommendation for the use of β‑blockers.5,9–11 Several 
randomized controlled trials and meta‑analyses have shown 
that when monotherapy is used for essential hypertension, 
β‑blockers and diuretics are equally effective at lowering 
BP compared with ACEIs, adrenergic receptor binders 
(ARBs), and calcium channel blockers (CCBs).19–25 Patients 
with hypertension and compelling indications such as HF 
or diabetes may benefit from treatment with β‑blockers 
because they have antiatherogenic, antiarrhythmic, and 
anti‑ischemic properties.26–28 Clinical trials have demon‑
strated the beneficial effects of β‑blockers in patients with 
coronary heart disease, post‑MI patients, and patients with 
diabetes.8,29–32
β-blockers for treatment  
of hypertension
There is a need to improve hypertension management 
in high‑risk patients, and optimal therapy choice may 
enhance both adherence and outcomes in the long term. 
Despite their proven cardiovascular benefits, β‑blockers 
are underused for the treatment of hypertension in patients 
with diabetes because of their perceived side effect 
profile.8,33,34 However, various agents within the class 
of β‑blockers have different pharmacologic properties, 
including receptor antagonism effects, resulting in variable 
clinical outcomes in terms of hemodynamic and metabolic 
effects and tolerability across the spectrum of cardiovas‑
cular diseases.35–40
Concerns about the use of β‑blockers as first‑line agents 
for hypertension have been raised because of a 2005 meta‑
analysis that found β‑blockers do not significantly reduce 
cardiovascular events, especially stroke, compared with other 
antihypertensive drug classes.41 However, atenolol was the 
β‑blocker evaluated in three quarters of the studies included 
in this meta‑analysis (the others were propranolol, oxprenolol, 
metoprolol, and pindolol). Atenolol does not reduce all‑cause 
mortality in hypertension long term compared with other 
agents.41 Another meta‑analysis of five randomized controlled 
trials with more than 17,000 patients found significantly 
higher mortality (relative risk [RR] = 1.13, 95% confidence 
interval [CI] = 1.02, 1.25) with atenolol compared with 
other agents.22 These analyses raise questions about whether 
atenolol is suitable for high‑risk patients with hypertension.
Atenolol, metoprolol (β1‑selective blockers), and 
 propranolol (a β1‑, β2‑blocker) are associated with decreased 
insulin sensitivity and lipid metabolism.35,41,42 However, the 
third‑generation nonselective β‑blocker carvedilol does 
not have a negative effect on glycemic control and has 
an overall neutral effect on lipids.35,42,43 Similar effects on 
metabolic parameters have been observed with nebivolol 
in patients with hypertension and diabetes.44 Moreover, 
in the Glycemic Effect in Diabetes Mellitus: Carvedilol‑
Metoprolol Comparison in Hypertensives (GEMINI) study, 
the occurrence and perceived burden of diabetes‑related 
symptoms was lower with carvedilol than with metoprolol 
tartrate in patients already taking an ACEI or ARB in addi‑
tion to diabetes and lipid‑lowering therapies.45 Half of the 
patients required additional BP‑lowering agents, starting 
with a diuretic. Improvements in symptom burden observed 
in GEMINI added to the established efficacy and tolerability 
profile of carvedilol, and support its continued use in patients 
with hypertension and diabetes. AACE recognizes the benefit 
of the vasodilating properties of carvedilol and nebivolol and 
has suggested that these agents may be beneficial in patients 
with hypertension and diabetes.9
The third‑generation β‑blockers such as labetalol, 
 carvedilol, and nebivolol reduce BP in part through 
 lowering peripheral vascular resistance (vasodilation) 
instead of reducing cardiac output as done by the older, 
 traditional β‑blockers.46 The vasodilatory action of labetalol, 
 carvedilol, and nebivolol may lessen the incidence of some 
adverse events associated with traditional β‑blockers. For 
example, peripheral vasodilation may reduce the incidence 
of cold extremities and lessen the effect on glucose 
 metabolism.47,48
Noncompliance with antihypertensive medications is 
 common and is a major cause of inadequate BP control.49 
 Polypharmacy is one common reason for medication 
 nonadherence, but a recent study of patients with diabetes 
taking an average of 4.1 medications found that unreported side 
effects were also responsible for selective noncompliance.50 
β‑blockers have been associated with many adverse effects, 
including worsening glycemic control, fatigue, cold 
 extremities, and sexual dysfunction. Studies have reported that 
physicians perceive β‑blockers to be less well tolerated than the 
other three antihypertensive classes of drugs, a point of view 
that is bolstered by studies such as the Losartan Intervention for 
 Endpoint Reduction (LIFE) trial and can influence prescription 
preferences.51,52 However, a number of randomized controlled 
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trials show that β‑blockers and diuretics are equally or better 
tolerated than ACEIs or CCBs.19,20,24,53–55
Adherence in hypertension
The clinical benefits provided by β‑blockers are only effective 
if patients adhere to medication treatment correctly and on 
a long‑term basis. Many factors may contribute to poor 
medication adherence, but side effect profiles of drugs and 
the complexity of dosing regimens are likely to be major 
factors. Reducing pill burden by prescribing a once‑daily 
agent (although not studied specifically in β‑blocker trials) 
has been shown to increase adherence, including in patients 
with hypertension.56
In a large‑scale study of medication adherence among 
2,325 patients with hypertension, only 39% of patients 
maintained therapy with one or more antihypertensive drugs 
throughout the 10‑year followup period.57 Approximately 
22% of patients temporarily stopped and restarted treatment, 
and 39% stopped treatment permanently. More patients 
starting on diuretics and β‑blockers stopped treatment 
(odds ratio [OR] = 1.15; 95% CI = 0.87, 1.52) compared 
with those starting on dihydropyridine calcium antagonists 
(OR = 0.54; 95% CI = 0.34, 0.84) and ACEIs (OR = 0.38; 95% 
CI = 0.27, 0.55). Patients also showed higher persistence when 
started on combination therapy (OR = 0.29; 95% CI = 0.14, 
0.54 compared with diuretics) or when initially treated by a 
cardiologist (OR = 0.82; 95% CI = 0.61, 0.97) or internist 
(OR = 0.80; 95% CI = 0.62, 0.98) compared with a general 
practitioner.57 Two factors in patient adherence to medication 
are the perceived symptoms and the perception of the therapy 
importance. It is important that the side effects of prescribed 
therapies are not worse than the disease symptoms, and that 
dosing instructions are as simple as possible for patients taking 
numerous medications. This is particularly problematic in the 
treatment of hypertension, because some medications may 
produce more adverse symptoms than the disease itself.58 Low 
compliance rates are prevalent in these patients.59 Patients with 
hypertension who have uncontrolled BP as a result of their 
poor medication‑taking behavior remain at risk for serious 
morbidity and mortality (eg, stroke, myocardial infarction, 
and kidney failure). Patients with diabetes and comorbid 
hypertension and/or dyslipidemia are at particularly high risk 
for nonadherence because of the polypharmacy required to 
treat hyperglycemia, hypertension, and/or hyperlipidemia.
In a study of compliance with prescribed medications in 
357 patients seen by family practice physicians and internists, 
the rates of adherence in both patients with HF (n = 123) 
and patients with diabetes (n = 234) was less than optimal.60 
Patients were taking up to 14 different drugs, and an asso‑
ciation was observed between the number of drugs and 
medication‑taking errors, including omission (proportion 
of drugs prescribed by the physician that the patient was not 
taking), commission (proportion of prescription drugs the 
patient was taking that the physician had not prescribed), 
scheduling misconception (proportion of prescribed drugs 
taken by the patient for which the patient did not know the 
correct schedule), and scheduling noncompliance (proportion 
of prescribed drugs taken by the patient for which the patient 
knew the correct schedule but did not take as prescribed). 
When all types of medication‑taking errors were combined, 
the average total error rate was 58%. Error rates for both 
commission and scheduling misconception errors increased 
as the complexity of the regimen (as measured by dosing 
frequency) increased.60
Reducing pill burden by prescribing a once‑daily agent 
may increase adherence, as shown in a systemic review of 
hypertension studies in which the highest adherence was 
found with once‑daily dosing and declined as the daily dose 
frequency increased.56 To improve outcomes among patients 
with hypertension, programs to detect poor medication adher‑
ence and support long‑term persistence must be developed 
and successfully implemented, using antihypertensive agents 
that promote and aid adherence through simplified dosing 
and high tolerability.61
Choosing β-blockers for optimal 
treatment of high-risk  
hypertensive patients
Atenolol
In clinical studies, especially the studies evaluated in recent 
meta‑analyses, atenolol 50 mg to 100 mg is typically a 
once‑daily therapy.41,62–64 However, this atenolol regimen 
may not provide a full 24 hours of blood pressure control. 
This is illustrated by a small, open‑label study involving 
36 patients with hypertension who were receiving hydro‑
chlorothiazide 12.5 mg, whereby adding 50 mg atenolol or 
metoprolol succinate once daily in the morning (force‑titrated 
to 100 mg at four weeks) provided lowered systolic blood 
pressures (SBP) during the midnight to six o’clock hours with 
 metoprolol tartrate (-7 mmHg), but not atenolol (3 mmHg; 
P = 0.03).65 Additionally, in another study of atenolol (50 to 
100 mg once daily), the decrease in diastolic blood pressure 
(DBP) values in the last six hours of the 24‑hour dosing 
period was significantly less than in the previous 18 hours 
(P  0.01).66 Night time and early morning BP control is 
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important because it is during these times that increases in 
cardiovascular morbidity are observed.65 The results of these 
studies may explain, in part, the reduced benefit regarding 
cardiovascular events attributed to β‑blockers (primarily 
atenolol) compared with other antihypertensive agents in 
the previously mentioned meta‑analysis.41 Moreover, delay‑
ing an atenolol dose may have clinically relevant effects on 
BP control.
Atenolol was also found to decrease insulin sensitivity 
and increase triglyceride levels and risk of new‑onset 
 diabetes compared with other antihypertensive classes in 
two large studies.67–69 In patients at high risk for diabetes or 
 dyslipidemia or who develop these conditions, atenolol may 
not be appropriate.
Metoprolol
Metoprolol is a relatively β1‑adrenergic receptor selective 
agent, but loses this selectivity at higher plasma concentra‑
tions.70 This agent has two formulations; an immediate‑
release (tartrate) and an extended‑release (succinate).71 The 
 immediate‑release formulation is a twice‑daily regimen, 
because at 100 mg once daily, metoprolol tartrate does not 
provide clinically relevant β1‑adrenergic receptor blockade 
(assessed by exercised‑induced tachycardia) in the last six 
hours of the 24‑hour dosing period.71 Additionally, maximum 
plasma concentrations have been shown to be as much as 
four‑fold higher with the immediate‑release formulation 
compared with the extended‑release formulation at 100 
mg.71 If patients with hypertension are unable to tolerate 
 metoprolol tartrate, a recommended alternative treatment 
endorsed by pharmacists is metoprolol succinate at the total 
daily metoprolol tartrate dose.72 If metoprolol succinate 
is not tolerated, another β‑blocker such as carvedilol or 
bisoprolol can be started 24 hours after the last metoprolol 
dose (see later for carvedilol dosing equivalence and see 
Table 3).72
Labetalol
Labetalol was the first β‑blocker to provide comprehensive 
adrenergic blockade.73 However, because of a short half‑life 
(six to eight hours), labetalol is administered as a twice‑daily 
medication and is not as convenient as once‑daily dosing 
for patients with hypertension who are taking multiple 
 medications.73 A key property of labetalol is that it lowers BP 
quickly (orally, within two hours; intravenously, in 10 minutes) 
and in a steady manner without clinically relevant changes in 
heart rate or cardiac output.73 Therefore, labetalol is ideally 
suited for use in hypertensive emergencies.74 Labetalol has 
also been found to be useful in the treatment of hypertension 
during pregnancy, especially severe hypertension, given that 
ACEIs and ARBs are contraindicated because of adverse 
effects.75
Labetalol has been well tolerated in general practice 
in patients with all stages of hypertension. A review of 11 
general practice studies involving 8573 patients reported that 
tiredness, dizziness, headache, and upper gastrointestinal 
symptoms were the most common adverse events during 
labetalol treatment.76 Moreover, except for headache, patients 
treated with labetalol 400 mg reported fewer of the common 
adverse events compared with propranolol and slow‑release 
oxprenolol. However, the incidence of adverse events dur‑
ing labetalol treatment appeared to be dose‑dependent. No 
published reports were found with labetalol in patients with 
diabetes or other conditions with a high risk of cardiovascular 
events. Nevertheless, in 81 patients with severe hypertension 
who received either labetalol‑based or methyldopa‑based 
therapy for up to one year, labetalol‑based therapy provided 
hypertension control (diastolic BP  90 mmHg) in 40% of 
patients, with nausea being the most commonly reported 
adverse event.77
Nebivolol
Nebivolol 5 mg is administered once daily and has been 
shown in clinical trials to be well tolerated in patients with 
hypertension, although there is no indication for ts use after 
an MI or in patients with HF. A recent open‑label, six‑week 
study of nebivolol (5 to 10 mg daily) in patients with mild 
hypertension (n = 6356) reported no serious adverse events 
and only 0.5% of patients reported any adverse event.78 
In a meta‑analysis of 12 studies involving 2653 patients 
with hypertension, the adverse events reported for nebivolol 
5 mg were higher than placebo (OR = 1.16; 95% CI, 
0.76–1.67; P = 0.482) but lower than other antihypertensive 
agents combined (ACEIs, ARBs, CCBs, atenolol, metoprolol 
tartrate, and bisoprolol; OR = 0.59; 95% CI, 0.48–0.72; 
P  0.001).79 In a three‑month, open‑label study in 2838 
patients with hypertension and Type 2 diabetes, nebivolol 
(2.5 to 10 mg daily) lowered BP to the recommended goal 
(130/80 mmHg) in 9.6% of patients and to a diastolic 
BP of  90 mmHg in 88% of patients.44 There was a small 
increase in physical capabilities that achieved statistical 
significance (P  0.001). Reported adverse events were 
low, comprising 0.3% of patients, with headache, fatigue, 
and nausea each reported in one patient. At study entry, 
approximately 40% of patients were receiving ACEIs and 
20% were receiving an ARB.
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Compared with atenolol 50 mg daily in patients with 
hypertension (n = 366), nebivolol 5 mg daily reduced the 
number of patients who reported fatigue (eight versus four, 
respectively).80 However, a similar number of patients reported 
dizziness (two versus three, respectively) and headache (four 
versus three, respectively). It has been reported in a recent 
review that similar results were obtained from a clinical trial 
comparing nebivolol with metoprolol.81
Carvedilol CR
The availability of carvedilol controlled‑release (carvedilol 
CR), a once‑daily formulation of carvedilol, allows for the 
choice of a β‑blocker that does not have adverse effects 
on glycemic control and is also convenient for patients. 
Carvedilol CR was approved by the US Food and Drug 
Administration (FDA) with the same indications as the 
original twice‑daily formulation (hypertension, post‑MI with 
left ventricular dysfunction, and HF).82 When prescribing 
any new medication, the discussion of adverse events (side 
effects) is important because it may be a barrier to patient 
adherence. Carvedilol CR has been well tolerated in the 
clinical trials conducted so far in patients with hypertension 
and with left ventricular dysfunction.83,84 In patients with 
uncomplicated hypertension, carvedilol CR was tolerated 
without an increase in total adverse events at the highest dose 
(80 mg once daily) compared with placebo.85
Recent studies have shown that carvedilol CR is effective 
in lowering BP. In a randomized, placebo‑controlled study 
that compared three doses of carvedilol CR (20, 40, and 
80 mg once daily) with placebo in patients with essential 
hypertension, the 24‑hour DBP fell in the placebo group 
and the three carvedilol CR groups (P  0.001, trend for all 
carvedilol CR doses compared with placebo).85 The mean 
SBP reduction at peak dose with carvedilol CR 80 mg was 
-15.3 mmHg.86
Dosing equivalence of carvedilol  
and carvedilol CR
Carvedilol CR has been shown to be therapeutically 
 equivalent to carvedilol, but with the benefit of once‑daily 
dosing. A number of investigations demonstrated that 
the pharmacokinetic and pharmacodynamic properties 
are equivalent between twice‑daily carvedilol and once‑
daily carvedilol CR; the two formulations were shown 
to be equivalent in all doses used in hypertension.87 For 
 hypertension treatment, carvedilol CR is available at doses 
of 10, 20, 40, and 80 mg; the equivalent carvedilol doses 
are shown in Table 2.82,88 It is the author’s opinion, based 
on Fonarow et al,88 that most patients currently on a stable 
carvedilol dose should start the equivalent carvedilol CR 
dose the day following their last evening dose of carvedilol. 
However, a recent update to the carvedilol CR prescribing 
information suggests that when switching from carve‑
dilol 12.5 mg or 25 mg twice daily, a lower starting dose 
of carvedilol CR may be considered for elderly patients 
(65 years) or those at increased risk of hypotension, diz‑
ziness, or syncope. Subsequent titration to higher doses 
should, as appropriate, be made after an interval of at least 
two weeks.
Dose equivalence of other  
β-blockers and carvedilol CR
It is important to understand dose equivalence among 
β‑blockers for the selection of an optimal regimen in patients 
with changing and complex needs, especially in patients who 
develop dyslipidemia or diabetes. The dose equivalencies 
shown in Table 3 are based on clinical experience and were 
chosen to maintain similar BP lowering levels. Replacing 
another β‑blocker with carvedilol CR is generally safe 
and well tolerated, but patients should be monitored to 
ensure medication compliance, degree of BP lowering, 
and tolerance. Possible adverse events associated with 
α‑blockade are dizziness and postural hypotension.
The recommended starting dose of carvedilol CR in 
patients with hypertension is 20 mg once daily. Although 
the prescribing information for carvedilol CR states that 
 uptitration should occur at one to two week intervals, it is 
the author’s opinion that in situations where carvedilol CR 
is replacing another β‑blocker, uptitration should occur at 
Table 2 Recommended algorithm for replacing carvedilol with 
carvedilol CR in patients with hypertension
Current dose of carvedilol   Starting dose of 
carvedilol CRb
6.25 mg (3.125 mg BID) Wait 12 hoursa 10 mg QD
12.5 mg (6.25 mg BID) 20 mg QD
25 mg (12.5 mg BID) 40 mg QD
50 mg (25 mg BID) 80 mg QD
Notes: aSuggestion for patients: Take the nighttime dose of carvedilol BID and start 
carvedilol CR the next morning. bWhen switching from carvedilol 12.5 mg or 25 mg 
BID, a lower starting dose of COREG® CR may be considered for elderly patients 
(65 years) or those at increased risk of hypotension, dizziness, or syncope. Subse-
quent titration to higher doses should, as appropriate, be made after an interval of 
at least two weeks. Recommendations are based on the author’s opinion, Coreg CR 
prescribing information,82 and data from Fonarow.88
Abbreviations: BID, twice daily; CR, controlled release; QD, once daily.
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two‑ to three‑day intervals as tolerated. Before prescribing 
carvedilol, all other medications should be stable. Other 
agents with vasodilatory properties (such as CCBs, 
nitrates, or other antihypertensives) should not be added 
to the patient’s regimen immediately before or during the 
 adjustment period.
Conclusions
Hypertension is the most common diagnosis in the primary 
care setting and can only be treated properly if the patient 
adheres to the medication regimen. In general, adherence 
to antihypertensive drugs is suboptimal and may be 
 further decreased by complicated drug regimens. Choice 
of antihypertensive therapy is a contributing factor to both 
 medication adherence and clinical outcomes. Even within 
a single antihypertensive class, such as the β‑blockers, the 
 clinical profile of the members may vary greatly. Consequently, 
information about the dosing, efficacy, tolerability, and 
 pharmacokinetic properties of the various agents is necessary 
in order to select the β‑blocker that is most appropriate for 
the individual patient. Although all β‑blockers are effective 
in reducing BP, they have very different hemodynamic, toler‑
ability, and metabolic profiles. The earlier β‑blockers, atenolol 
and metoprolol, may require a twice‑daily regimen and may 
result in glucose and lipid metabolism abnormalities. Nebivo‑
lol is a once‑daily β‑blocker for the treatment of hypertension 
with neutral metabolic properties; however, it is not indicated 
after an MI or if a patient progresses to HF. The availability 
of carvedilol CR, a once‑daily formulation of carvedilol, will 
result in an easier dosing regimen while retaining the neutral 
metabolic properties that make carvedilol a desirable agent 
in high‑risk patients with hypertension.
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Table 3 Suggested dose equivalences between other β-blockers and carvedilol CR in hypertension
Current β-blocker Carvedilol CR
Starting dosea Uptitration (after several days 
to one week) as toleratedb
Atenolol
Wait 24 hours from last dose  
of once-daily atenolol
Carvedilol CR Carvedilol CR
50 mg QDc 20 mg QD 40 mg QD
75 mg QD 40 mg QD 80 mg QD
Metoprolol tartrate
Wait 12 hours from last dose  
of metoprolol tartrate
25–50 mg BID 20 mg QD 40 mg QD
75–100 mg BID 40 mg QD 80 mg QD
100 mg BID 40–80 mg QD 80 mg QD
Metoprolol succinate
Wait 24 hours from last dose  
of metoprolol succinate
50–100 mg QD 20 mg QD 40 mg QD
150–200 mg QD 40 mg QD 80 mg QD
200 mg QD 40–80 mg QD 80 mg QD
Notes: aIn clinical trials, carvedilol CR was initiated in β-blocker-naive patients at 20 mg. The recommendations in this table are based on the author’s clinical and research 
 experience and, therefore, recommend switching patients already on a medium to high dose of another β-blocker to a medium to high dose of carvedilol CR. A caveat, however: 
older patients (65 years), patients with diabetic neuropathy, or those predisposed to orthostatic hypotension should generally start at 20 mg if on a low dose of another 
β-blocker and 40 mg if on a high dose of another β-blocker. Such patients may then be uptitrated as tolerated; switching directly to 80 mg is not recommended in these patients. 
 Physicians should closely monitor all patients to avoid possible worsening of BP and increases in heart rate after switching to 20 or 40 mg of carvedilol CR, which would call 
for a quicker uptitration. bUptitrate to achieve BP goal. Maximal dose is 80 mg daily (equivalent to 25 mg of carvedilol BID). cIf patients are on a dose of atenolol lower than 
50 mg (ie, 25 mg/day) it is unclear what the exact dose of carvedilol CR would be; however, patients at this low a dose should not be started on a dose higher than 20 mg of 
carvedilol CR.
Notes: Physicians should be guided by their own judgment and experience in choosing doses when switching between drugs.
Abbreviations: BID, twice daily; QD, once daily.
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